Efficacy and safety of canagliflozin as add‐on therapy to teneligliptin in Japanese patients with type 2 diabetes mellitus: Results of a 24‐week, randomized, double‐blind, placebo‐controlled trial
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Aims: To investigate efficacy and safety of the sodium–glucose co‐transporter 2 ( SGLT2 ) inhibitor canagliflozin administered as add‐on therapy to the dipeptidyl peptidase‐4 ( DPP ‐4) inhibitor teneligliptin in patients with type 2 diabetes mellitus ( T2DM ). Materials and methods: We conducted a multicentre, randomized, double‐blind, placebo‐controlled, phase 3 clinical trial in J apanese patients with T2DM who had inadequate glycaemic control with teneligliptin. Patients were randomized to receive teneligliptin 20 mg plus either canagliflozin 100 mg ( T + C , n = 70) or placebo ( T + P , n = 68) once daily. The primary endpoint was the change in glycated haemoglobin ( HbA1c ) from baseline to week 24. Other endpoints included changes in fasting plasma glucose, body weight, proinsulin/ C ‐peptide ratio, homeostatic model assessment 2‐% B and adverse events. Patients also underwent mixed‐meal tolerance tests. Results: The difference between the T + C and T + P groups for HbA1c change from baseline to week 24 was −0.88% (least‐squares mean, P < .001). Fasting plasma glucose, body weight and the proinsulin/ C ‐peptide ratio were significantly lower in the T + C group than in the T + P group. Homeostatic model assessment 2‐% B improved with T + C compared with T + P . The T + C group exhibited a decrease in the 2‐hour postprandial plasma glucose and plasma glucose area under the curve ( AUC ) 0‐2h in a mixed‐meal tolerance test. No significant between‐group differences were observed for C ‐peptide AUC 0 ‐2h or glucagon AUC 0 ‐2h after meals. Incidences of adverse events were 60.0% and 47.1% in the T + C and T + P groups, respectively. No hypoglycaemia was observed. Conclusions: Canagliflozin administered as add‐on therapy to teneligliptin was effective and well tolerated in J apanese T2DM patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diabetes in Asia: Epidemiology, Risk Factors, and Pathophysiology
Chan, J. C. N., Malik, V., Jia, W., Kadowaki, T., Yajnik, C. S., Yoon, K.-H., & Hu, F. B. (2009) · JAMA · doi:10.1001/jama.2009.726 · Cited by 1,997
Self-citationMetabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients
Ferrannini, E., Muscelli, E., Frascerra, S., Baldi, S., Mari, A., Heise, T., Broedl, U. C., & Woerle, H.-J. (2014) · Journal of Clinical Investigation · doi:10.1172/jci72227 · Cited by 1,134
Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production
Merovci, A., Solis-Herrera, C., Daniele, G., Eldor, R., Fiorentino, T. V., Tripathy, D., Xiong, J., Perez, Z., Norton, L., Abdul-Ghani, M. A., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci70704 · Cited by 795
Cited by
Japanese clinical practice guideline for diabetes 2019
Araki, E., Goto, A., Kondo, T., Noda, M., Noto, H., Origasa, H., Osawa, H., Taguchi, A., Tanizawa, Y., Tobe, K., et al. (2020) · Diabetology International · doi:10.1007/s13340-020-00439-5 · Cited by 545
Japanese Clinical Practice Guideline for Diabetes 2019
Araki, E., Goto, A., Kondo, T., Noda, M., Noto, H., Origasa, H., Osawa, H., Taguchi, A., Tanizawa, Y., Tobe, K., et al. (2020) · Journal of Diabetes Investigation · doi:10.1111/jdi.13306 · Cited by 341
Donnan, J. R., Grandy, C. A., Chibrikov, E., Marra, C. A., Aubrey-Bassler, K., Johnston, K., Swab, M., Hache, J., Curnew, D., Nguyen, H., et al. (2019) · BMJ Open · doi:10.1136/bmjopen-2018-022577 · Cited by 222
Odutayo, A., da Costa, B. R., Pereira, T. V., Garg, V., Iskander, S., Roble, F., Lalji, R., Hincapié, C. A., Akingbade, A., Rodrigues, M., et al. (2021) · Journal of the American Heart Association · doi:10.1161/jaha.120.019918 · Cited by 29
Metadata
- Authors
- Kadowaki, T., Inagaki, N., Kondo, K., Nishimura, K., Kaneko, G., Maruyama, N., Nakanishi, N., Iijima, H., Watanabe, Y., & Gouda, M.
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2017-03-31
- Volume
- 19
- Issue
- 6
- Pages
- 874-882
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- OpenAlex
- W2586681261
- Cited by
- 57
- References
- 3
- FWCI
- 5.94
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Efficacy and safety of canagliflozin as add‐on therapy to teneligliptin in Japanese patients with type 2 diabetes mellitus: Results of a 24‐week, randomized, double‐blind, placebo‐controlled trial. https://app.cochat.ai/papers/10.1111/dom.12898
- The paper
- Kadowaki, T., Inagaki, N., Kondo, K., Nishimura, K., Kaneko, G., Maruyama, N., Nakanishi, N., Iijima, H., Watanabe, Y., & Gouda, M. (2017). Efficacy and safety of canagliflozin as add‐on therapy to teneligliptin in Japanese patients with type 2 diabetes mellitus: Results of a 24‐week, randomized, double‐blind, placebo‐controlled trial. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.12898
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.